Healthcare Industry News: meniscal repair
News Release - June 3, 2010
Cayenne Medical Appoints Michael Gillem as Vice President of Sales
SCOTTSDALE, Ariz., June 3 -- (Healthcare Sales & Marketing Network) -- Cayenne Medical, Inc., a privately held sports medicine device company, announced the appointment of Michael T. Gillem as Vice President of Sales, effective June 1, 2010. Gillem, who will be responsible for the direction and management of all sales activities for the Company's AperFix® and CrossFix™ systems, brings more than 18 years of medical device industry sales and sales management experience."We are very pleased to welcome Mike to the Cayenne management team and believe he will be essential in helping us expand sales teams for our ACL and meniscal repair product lines," said James W. Hart, President and CEO of Cayenne Medical. "He has a proven, results-driven track record and I am confident his leadership will help shape the growth of our company."
Prior to joining Cayenne Medical, Gillem served as Vice President of Sales at Stereotaxis where his leadership helped deliver a 27 percent increase of revenue in 2009 compared to 2008. Gillem has also held several senior level positions helping to introduce technology to the marketplace and drive clinical adoption. As Area Director of Foxhollow Technologies, Gillem helped grow the company to over 200 sales professionals, which resulted in significant revenue growth.
Gillem received his Bachelor of Science degree from Purdue University.
About Cayenne Medical, Inc.
Based in Scottsdale, Arizona, Cayenne Medical is a privately held medical device company defining new technology for the soft tissue reconstruction segment of the sports medicine market. The company was founded in 2005 and is focused on leading the transformation of traditional ACL, PCL and meniscal repair procedures, by applying advanced technology through minimally invasive techniques. For more information, go to www.cayennemedical.com.
Source: Cayenne Medical
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
